Cited 40 times in
microRNA-944 overexpression is a biomarker for poor prognosis of advanced cervical cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 정다은 | - |
dc.date.accessioned | 2020-02-26T06:28:54Z | - |
dc.date.available | 2020-02-26T06:28:54Z | - |
dc.date.issued | 2019 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/175168 | - |
dc.description.abstract | BACKGROUND: One-third of cervical cancer patients are still diagnosed at advanced stages. The five-year survival rate is decreased in about 50% of advanced stage cervical cancer patients worldwide, and the clinical outcomes are remarkably varied and difficult to predict. One of the miRNAs known to be associated with cancer tumorigenesis is miR-944. However, the prognostic value of miR-944 in cervical cancer has not been fully investigated. The aim of this study was to analyze clinical significance and prognostic value of miR-944 in cervical cancer. METHODS: The expression levels of miR-944 were detected using quantitative reverse transcription polymerase chain reaction in five types of cervical cancer cell lines and 116 formalin-fixed paraffin-embedded (FFPE) cervical tissues. The association between the expression levels of miR-944 and prognostic value was analyzed using the Kaplan-Meier analysis and Cox proportional hazards model. RESULTS: The expression levels of miR-944 in cervical cancer tissues were significantly higher compared with those in normal tissues (P < 0.0001). Moreover, the expression levels of miR-944 in cervical cancer cell lines and FFPE tissues with human papillomavirus (HPV) infection were significantly higher compared to those without HPV infection (P < 0.01 and P = 0.02). High miR-944 expression was also markedly associated with bulky tumor size (P = 0.026), advanced International Federation of Gynecology and Obstetrics (FIGO) stage (P = 0.042), and lymph node metastasis (P = 0.030). In particular, high miR-944 expression group showed shorter overall survival than the low miR-944 expression group in the advanced FIGO stage (84.4% vs. 44.4%, HR = 4.0, and P = 0.01). CONCLUSIONS: These results suggest that miR-944 may be used as a novel biomarker for improving prognosis and as a potential therapeutic target. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | BioMed Central | - |
dc.relation.isPartOf | BMC CANCER | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Biomarkers, Tumor/genetics | - |
dc.subject.MESH | Biomarkers, Tumor/metabolism* | - |
dc.subject.MESH | Cell Line, Tumor | - |
dc.subject.MESH | Cervix Uteri/pathology | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Gene Expression Regulation, Neoplastic* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Kaplan-Meier Estimate | - |
dc.subject.MESH | Lymphatic Metastasis | - |
dc.subject.MESH | MicroRNAs/genetics | - |
dc.subject.MESH | MicroRNAs/metabolism* | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Neoplasm Staging | - |
dc.subject.MESH | Papillomavirus Infections/genetics* | - |
dc.subject.MESH | Papillomavirus Infections/mortality | - |
dc.subject.MESH | Papillomavirus Infections/pathology | - |
dc.subject.MESH | Papillomavirus Infections/virology | - |
dc.subject.MESH | Prognosis | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Up-Regulation | - |
dc.subject.MESH | Uterine Cervical Neoplasms/genetics* | - |
dc.subject.MESH | Uterine Cervical Neoplasms/mortality | - |
dc.subject.MESH | Uterine Cervical Neoplasms/pathology | - |
dc.subject.MESH | Uterine Cervical Neoplasms/virology | - |
dc.title | microRNA-944 overexpression is a biomarker for poor prognosis of advanced cervical cancer | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Obstetrics and Gynecology (산부인과학교실) | - |
dc.contributor.googleauthor | Sunyoung Park | - |
dc.contributor.googleauthor | Jungho Kim | - |
dc.contributor.googleauthor | Kiyoon Eom | - |
dc.contributor.googleauthor | Sehee Oh | - |
dc.contributor.googleauthor | Sunghyun Kim | - |
dc.contributor.googleauthor | Geehyuk Kim | - |
dc.contributor.googleauthor | Sungwoo Ahn | - |
dc.contributor.googleauthor | Kwang Hwa Park | - |
dc.contributor.googleauthor | Dawn Chung | - |
dc.contributor.googleauthor | Hyeyoung Lee | - |
dc.identifier.doi | 10.1186/s12885-019-5620-6 | - |
dc.contributor.localId | A03589 | - |
dc.relation.journalcode | J00351 | - |
dc.identifier.eissn | 1471-2407 | - |
dc.identifier.pmid | 31060525 | - |
dc.subject.keyword | Prognosis | - |
dc.subject.keyword | Survival | - |
dc.subject.keyword | Uterine cervical neoplasm | - |
dc.subject.keyword | microRNAs | - |
dc.contributor.alternativeName | Chung, Da Wn | - |
dc.contributor.affiliatedAuthor | 정다은 | - |
dc.citation.volume | 19 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 419 | - |
dc.identifier.bibliographicCitation | BMC CANCER, Vol.19(1) : 419, 2019 | - |
dc.identifier.rimsid | 64166 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.